











































Real-world evidence to support Payer/HTA decisions about
highly innovative technologies in the EU-actions for stakeholders
Citation for published version:
Facey, KM, Rannanheimo, P, Batchelor, L, Borchardt, M & de Cock, J 2020, 'Real-world evidence to
support Payer/HTA decisions about highly innovative technologies in the EU-actions for stakeholders',
International journal of technology assessment in health care, vol. 36, no. 4, pp. 459 - 468.
https://doi.org/10.1017/S026646232000063X
Digital Object Identifier (DOI):
10.1017/S026646232000063X
Link:




International journal of technology assessment in health care
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.




Manuscript Accepted for  




REAL-WORLD EVIDENCE TO SUPPORT PAYER/HTA DECISIONS ABOUT HIGHLY 
INNOVATIVE TECHNOLOGIES IN THE EU - ACTIONS FOR STAKEHOLDERS  
 
Karen M. Facey BSc PhD (Statistics)  (corresponding) 
Senior Research Fellow, Usher Institute, University of Edinburgh, Nine Bioquarter, 9 Little 
France Road, Edinburgh, EH16 4UX. UK 
Email: karen.facey@ed.ac.uk 
Phone: +44 (0)789 414 3931 
 
Piia Rannanheimo, MSc (Pharm.) 
Pharmacoeconomist, Finnish Medicines Agency, P.O.Box 55, FI-00034 Finland.  
Email: piia.rannanheimo@fimea.fi 
 
Laura Batchelor MA (Languages) 
Partner, FIPRA, Rue de la Loi 227, 1040 Brussels, Belgium. 
Email: laura.batchelor@fipra.com 
 
Marine Borchardt BA LLM MA (Law and Politics)  
Senior Account Executive, FIPRA, Rue de la Loi 227, 1040 Brussels, Belgium. 
Email: marine.borchardt@fipra.com 
 
Jo De Cock MA (Law, Criminology)  
CEO, National Institute for Health and Disability Insurance (RIZIV/INAMI), Tervurenlaan 211, 







There are divergent views on the potential of real-world data (RWD) to inform decisions 
made by regulators, HTA bodies, Payers, clinicians and patients. This RWE4Decisions 
initiative explored the particularly challenging setting of highly innovative technologies, which 
require Payers/HTAs to make decisions on a small evidence base with major uncertainties. 
The aim was to go beyond strategic intent to consider actions that each stakeholder could 
take to improve use of RWD in this setting. 
 
Results 
Case studies of recent Payer/HTA assessments about highly innovative technologies were 
considered in light of recent international initiatives about RWD. This showed a lack of clarity 
about the Payer/HTA questions that could be answered by RWD and how the quality of real-
world evidence (RWE) could be assessed. All stakeholders worked together to create a vision 
whereby stakeholders agree what RWD can be collected for highly innovative technologies 
based on principles of collaboration and transparency. For each stakeholder group, 
recommended actions to support the generation, analysis and interpretation of RWD to inform 
decision-making were developed.  For HTA bodies, this includes cross border HTA/regulatory 
collaboration to agree RWD requirements over the technology life cycle to inform initial 
recommendations and reassessment, data analytics methods development for HTA and 






Stakeholders need to collaborate on demonstration projects to consider how RWE can be 
developed to inform healthcare decisions and contribute to a learning network that can 
develop systems to support a learning health system and improve patient outcomes through 
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Highly innovative technologies (such as immuno-, cell and gene therapies that use novel 
molecular biology to target the underlying cause of a disease) aim to deliver transformative 
patient benefit. Where large potential benefit is expected in areas of high unmet medical need 
(such as in rare diseases), regulators have developed expedited pathways. Regulatory 
approval based on interim analyses of short-term endpoints and early data cut-offs is common, 
as is the use of uncontrolled trials.  This means that some health technologies enter the market 
with a limited evidence base to demonstrate clinical effectiveness.   
 
There is substantial pressure for Payers (or HTA bodies) to make (or inform) pricing and 
reimbursement decisions about these technologies at the point of market launch. However, 
uncertainties exist about the population to be treated, natural history of disease, size and 
durability of clinical effects compared to treatment alternatives, safety, cost effectiveness and 
budget impact. As, these highly innovative technologies often have a high price due to the 
complexity of development and purported high patient benefit, decisions about their value are 
challenging.   
 
Although less than twenty cell and gene therapies had received regulatory approval by the 
end of 2019 in the EU, in early 2020 there were 1,000 clinical trials underway in over 400 
companies (1,2), so Payers/HTA need to quickly find ways to evolve their decision-making 
processes to help resolve uncertainties and mitigate risks.  One option is to consider a 
longitudinal approach to evidence generation with collection of real-world data (RWD) over 
the life cycle of the technology (3).  
 
The potential to use RWD to make decisions about highly innovative technologies links into 
the major scientific and technological advancements in digital health (4, 5). Numerous national 
and transnational collaborations are expected to contribute to improvements in quality, 
coverage and access to RWD (6, 7, 8) and have the potential to create learning health systems 
that will improve patient outcomes (9).  The health technology industry, health systems, 
clinicians, patients and methodologists are working to improve use of real-world/big data in 
the healthcare sector. However, views differ on how RWD can be used and the potential to 
generate robust reliable real-world evidence (RWE) to inform major decisions.  
 
Regulators have used RWE for many years for pharmacovigilance and have recently 
developed frameworks for use of RWE in wider regulatory contexts, but continue to state 
that evidence from randomised-controlled trials (RCT) remains the best available standard 
for demonstration of efficacy and such data should be seen as complementary to RCT 
evidence (12, 7). Medical and regulatory leaders across the EU (13) have highlighted that 
the evidence requirements for each regulatory decision are not the same. Acceptability is 
influenced by the question being asked, the level of risk and other considerations such as 
the ability to capture other data, availability of other treatments and unmet medical need. 
Such contextual considerations also influence Payer/HTA views on the persuasiveness of 
RWE (14, 15). In the US, it has been stated that demonstration of superiority, expansion of 
use, contradiction with RCT results or major change in clinical practice will all require a “high 
evidence bar”. Whereas assertion of equivalent effectiveness and lower cost, a new safety 
signal and complementing RCT data to fill gaps may all be “low evidence bar” situations 
(16). Both regulators and Payers/HTA agree that acceptability of RWE is dependent on data 
and methodological processes to control for bias and confounding. 
 
In 2017, the CEO (de Cock) of the National Institute for Health and Disability Insurance- 
INAMI/RIZIV (the Belgian healthcare payer) initiated a series of multi-stakeholder initiatives to 




decisions, particularly in relation to rare disease treatments. The resulting reports included 
principles for use of RWD over the entire technology life cycle (3) and for Outcomes-Based 
Managed Entry Agreements (OB-MEA) (18). Annemans and Makady (19) reported on the 
TRUST4RD initiative, producing a Tool for Reducing Uncertainties in the evidence generation 
for Specialised Treatments for Rare Diseases. It included a taxonomy of 
evidence/uncertainties that arise with rare disease treatments to support iterative multi-
stakeholder dialogues and recognized that RWE may be able to resolve uncertainties about 
natural history, the interaction between the technology and the disease (including long-term 
treatment effects), and uncertainties related to the healthcare ecosystem.  
 
Although these were multi-stakeholder initiatives with broad buy-in, there was still a lack of 
uptake and little advancement in use of RWD for decision-making. Hence it was decided to 
consider how these three initiatives and other ongoing RWD policy activities could be applied 
to the challenges associated with Payer/HTA decisions for highly innovative treatments, which 
was an issue that loomed large in 2019. 
 
This initiative, RWE4Decisions was commissioned by INAMI/RIZIV to explore with all 
stakeholders the potential use of RWD in this specific case of making Payer/HTA decisions 
about highly innovative technologies and agree clear actions. It excluded consideration of 
underpinning issues about data sources, methodologies, governance, analytics and 
infrastructure that were being addressed by others (6, 20). 
 
This paper explains the methods used and the resulting vision and key principles. It outlines 
key stakeholder roles in relation to RWD and proposes actions for each stakeholder group to 
test the use of RWD to inform Payer/HTA decisions about highly innovative technologies. 
Finally, consideration is given to how a multi-stakeholder learning network for RWE can be 
established to align work with other initiatives, share best practices and develop guidance that 





All work was undertaken according to the ‘Bad Gastein’ principle of equal representation of all 
stakeholders from the fields of public health and healthcare (21). Representatives from HTA 
bodies, payers, regulators, government bodies, clinical research organizations, 
pharmaceutical industry, patient groups and academia participated in meetings and email 
consultations (the Review Group) and a sub-group involving all stakeholders brainstormed 
ideas arising between each step via teleconference (the Task Force). This work linked into the 
EU Finnish Presidency program in 2019 on the “economy of well-being” that included 
discussion about using RWD for evaluation of the value of pharmaceuticals, and included 
consultation as outlined below. 
 
A mixed-methods approach was used that explored recent policy proposals about use of RWD 
applied to the specific context of Payer/HTA decisions about highly innovative technologies 
and developed feasible actions that were implementable by each stakeholder group. 
Workshops, teleconference and email consultations were used over several months as 
follows:  
 
• Presentations from the Finnish Health/Pharmaceutical Attache to the EU, a payer 
collaborative, HTA bodies and a European clinical network explored the challenges 
with use of RWE to resolve the Payer/HTA uncertainties emerging with highly 
innovative technologies. A roundtable discussion drawing in European patient groups 




• Desk top research – Selected policy documents from the EU and USA about the use 
of RWD in regulatory and HTA decision-making published from January 2018-April 
2019 were reviewed and discussed to avoid “reinventing the wheel”. 
• Case studies – Members of the initiative were asked to put forward case studies of 
marketed highly innovative technologies where RWE was pivotal to reimbursement 
decisions or where challenges in RWD collection remained.  This resulted in one 
case study from HTA (relating to nusinersen), one from a Payer (relating to 
tisagenleceucel) and two confidential topics from industry. 
• Development of stakeholder actions – After the case study workshop, each individual 
wrote down actions they felt were needed by each stakeholder to make consistent use 
of RWD in Payer/HTA decisions become a reality. Actions were discussed on the day, 
then amalgamated and refined by the Taskforce and their networks over several 
months, including a presentation to the EU Chief Pharmaceutical Officers.  
• Version 1 of the stakeholder roles and actions were issued publicly for 3 months 
consultation with a specific request to encourage European stakeholder groups to 
respond. The actions were also presented at international meetings for feedback. 
Detailed feedback was received from eleven expert groups and major revisions were 
made to the actions. The revised actions were then reviewed by the Task Force and 
finalized by the authors. 
 
Meetings were chaired by de Cock and an ex EU parliamentarian. Facey undertook the 
desktop research, facilitated the workshop and helped prepare materials with Batchelor and 
Borchardt who organised all meetings. Rannanheimo was the key link to the Finnish EU 
Presidency and provided substantial input to the redrafting of the recommended actions and 





The Potential for Use of RWD in Decision-Making in the EU 
 
The initial stakeholder presentations and discussions with stakeholders identified that EU 
Member States (MS) differ markedly in their digital health capabilities. Some have excellent 
electronic health (and other government) records that can be linked via a unique patient 
identifier (Finland, Scotland, Norway, Sweden, France), but analyses can be cumbersome and 
key information such as diagnosis may not be recorded on prescriptions. Other MS have 
developed bespoke registries to monitor appropriate utilization of new pharmaceuticals and 
enable OB-MEA (Italy, Portugal). Hence the landscape for RWD collection is disparate across 
the EU and the infrastructure and governance frameworks to enable data sharing across EU 
MS do not yet exist. Initiatives are underway to address these concerns (13, 8) at an 
international policy level, but these are complex and will take time. So, this work focused on 
the specific issue of making pricing and reimbursement decisions about highly innovative 
technologies, seeking to develop feasible actions for each stakeholder at a national or 
transnational level that could be enacted now and in the near future. 
 
The desktop research identified recent initiatives to support use of RWE in healthcare 
decision-making. These all highlighted the need for developments in data governance to 
enable appropriate data sharing according to data protection legislation and robust 
methodological approaches to address biases. Key elements about the potential use of RWD 





Table 1. Stakeholder Views on RWE in Decision-Making 







Novel insights on use and 
performance of medicines, 
complementing RCT evidence 
• Epidemiology 
• Contextualize efficacy 




Evidentiary standards for RWE that take 
account of context 
• Adequate range of characteristics of 
population covered 
• Good quality RWD sources with data 
that are quality assured 
• Agreement on common core data 
elements 






Registries initiative to promote dialogue about use of 






Operational (data infrastructure) 




- extent and completeness of data 
- appropriate terminology and data formats 
- potential for data linkage 
- consistent, accurate and timely data collection and 
management 
Methodological 
- understanding of data source 
- evaluation of variability in multi-data source studies  
- adequate data collection and analysis on potential 




HMA-EMA joint Big Data Task Force informing EU 
strategy to 2025 to seize the opportunity for data-










 Potential uses of RWE What do we need? Initiatives 
HTA Resolution of uncertainties in 
determination of value 
 
Initial HTA 
• describe current standard of care 
• create external comparator to 
contextualize efficacy 
• populate cost effectiveness and 
budget impact models. 
Managed entry agreement 
• evaluate outcomes in clinical 
practice 
• resolve uncertainties related to 
determination of value in the initial 
assessment 
Re-assessment 
• complement the clinical and 
economic evidence base that was 
available in the initial assessment 
• monitor utilisation and evaluate 
budget impact in clinical practice. 
 
Agreement across HTA programmes and 
HTA bodies about the potential for use of 
RWE, development of analytics expertise to 
support RWE critical assessment and 
cross-organisational collaboration to   
• Identify data gaps/HTA questions that 
may be resolved by RWE 
• Develop capacity and tools to support 
understanding of issues relating to 
curation and synthesis of RWD from 
different sources 
• Create tools to support critical 
assessment of uncontrolled RWE 
studies, particularly selection bias, lack 
of blinding, time varying confounders 
• Develop infrastructure to support cross 
organisational sharing of RWE 
generation plans and post-licensing 
evidence generation 
 
EUnetHTA REQueST tool evaluates data quality and 
usability of clinical registries for HTA purposes 
https://eunethta.eu/request-tool-and-its-vision-paper/ 
 





ICER - RWE for Coverage Decisions: 





NICE Decision Support Unit – RWD for estimation 
of treatment effects 
http://nicedsu.org.uk/methods-development/real-
world-data/  
Clinicians Optimal use of the technology in 
clinical practice 
• Monitor outcomes and adverse 
events to inform treatment 
decisions with individual patients 
• Optimize treatment regimen 
(dosing and who to treat)   
• Optimize therapeutic strategies 
(place in pathway) 
• Benchmark equity of access 
across health systems 
 
Patient, rather than treatment centred 
approaches sharing data across Europe 
 
European Reference Networks – development of 









 Potential uses of RWE What do we need? Initiatives 
Patients Explaining the “real-world” experience 
of patients 
• Evaluating unmet needs 
• Measuring patient benefit and 
disbenefit measuring outcomes 
that matter to patients 
 
 
Systematic patient involvement in RWD 
collection 
• Responsible health data sharing that 
builds patients’ awareness and trust 
• Dynamic consent to give patients the 
power to approve use of their data on a 
case-by-case basis, for example using digital 
models of iterative opt-in/opt-out. 
• Avoidance of duplication with disease-
based rather than treatment-based 
registries that can identify the specific 
patients that may be required for an 
HTA/regulator evaluation 
• Monitoring of inequalities to treatment 
access across Europe 
 
#DataSavesLives initiative promotes greater 
awareness among patients of how health data can be 
used in trustworthy ways to improve health and care. 
https://datasaveslives.eu/ 
 
Office of Health Economics Legal barriers to better 








Throughout the life cycle of the 
technology  
• Develop understanding of 
therapeutic landscape and unmet 
needs 
• Early clinical development 
• Natural history 
• Safety 
• Clinical effectiveness 
• Economic modelling 
• Innovative pricing agreements 
Overcome political, economic, societal, 
technical and legal barriers that hinder data 
collection and use 
• Investment in digital health 
infrastructure and harmonization across 
the EU 
• Alignment of RWE requirements pre- 
and post-licensing across HTA/payer 
bodies in the EU and with EMA 
• Consensus on quality and reliability of 
RWD sources to inform decisions 
• Adoption of new approaches to RWE 
generation earlier in the technology life 
cycle   





imi GETReal developing new methods for RWE 







EFPIA European Federation of Pharmaceutical Industries and Associations; EMA European Medicines Agency; EU European Union; HMA Heads of Medicines Agencies; EUnetHTA EU network for 




RWE4Decisions – Actions for Each Stakeholder Group  
 
Case studies were discussed in multi-stakeholder workshops, to see if existing initiatives 
provided sufficient guidance to inform Payer/HTA discussions about RWD. All stakeholders 
agreed that the large number of initiatives showed fragmentation of approaches with divergent 
guidance emerging. Siloed working had led to a lack of clarity about what RWD might be 
suitable for what questions and how that could be developed into robust RWE to inform Payer 
decisions. This led to the recognition by all stakeholder groups that collaboration is essential 
and that this must be underpinned by trust and transparency as outlined in the vision and key 
principles (Figure 1). To ensure that development of RWE is seen as a shared responsibility 
the roles of each stakeholder to support the generation, analysis and interpretation of RWD to 
inform decision-making were clarified as outlined in Table 2.  
 













Identifying the questions that can/should be answered with RWD/RWE, providing 
guidance on critical assessment of RWE, collaborating with other stakeholders to 
collect, analyse and interpret RWD, implementing innovative payment models 
based requiring RWE generation 
Regulators   Ensuring RWD collection strategies (such as registries) are multi-stakeholder and 




Actively engaging with other stakeholders to develop and implement plans for 
RWD collection, analysis and reporting over the lifecycle of a highly innovative 




Involving all stakeholders in the establishment of registries and ensuring good 
governance that addresses data quality, accessibility and sustainability to ensure 
the long-term value of registries and avoidance of waste in research  
Clinicians and 
patients 
Contributing real-world experience to support collection and generation of RWD 
that is useful and informs decision-making at individual level, and population-level 
to create RWE 
Patient groups As authorised representatives of patients, engaging in co-creation of RWD/RWE, 
communicating the possible uses of RWD and good governance processes to 
encourage patient involvement 
RWD/analytics 
groups2 
Curation and analysis of RWD from electronic health records and other sources 
such as claims databases, government records etc with a commitment to 
transparency, replicability and principled database epidemiology 
 
1. EMA uses the term ‘registry coordinator’ - a person or entity having a role in the overall coordination of a registry 
or of a platform of several registries. Registry holders can be patient groups, healthcare professionals, clinical 
institutes, manufacturers 
2. These groups could be within the health sector, academia or private sector consultancies. 
 
Working within the principles of collaboration and transparency, each stakeholder can 
undertake actions to support the use of real-world evidence in Payer/HTA decisions about 
highly innovative technologies. Table 3 presents the recommended actions for each 
stakeholder group that have been modified over several iterations with the Taksforce, Review 
Group and public consultation, with final amendments by the authors. These 
recommendations are more fulsome for Payer/HTA bodies and pick up on recommendations 






Table 3. RWE4Decisions Stakeholder Actions  
Payers/HTA bodies 
1. European or Multi-Country HTA or Payer Collaboratives 
1.1 Collaborate with academia to better understand the potential of new statistical, econometric and modelling approaches to develop robust real-
world evidence (RWE) for use in Payer/HTA decisions.  
1.2 Encourage industry to engage in multi-stakeholder dialogues to discuss evidence generation plans including real-world data (RWD) collection. 
1.3 Use joint processes (multi-HTA and with regulators) to document evidence gaps and key uncertainties in the clinical (and economic) evidence 
and identify which areas might be addressed by patient-relevant RWE.  
1.4 Document the regulatory post-licensing evidence generation (PLEG) obligations and the additional Payer/HTA PLEG needs. Establish what 
PLEG is needed on national, regional, and European level.   
1.5 For individual HTAs, agree the core dataset that is required for HTA reappraisal, within a reasonable timeframe, so that common data collection 
protocols can be agreed across countries and joint analyses performed. 
1.6 Engage with the clinical community, particularly European Reference Networks (ERNs), to avoid conflicting or duplicative data collection. 
1.7 Develop methods guides to show how RWE will be critically assessed and how the validity and applicability of RWD/RWE from another 
country/health setting will be determined. 
1.8 Encourage the development of a public portal registering RWE studies that may be used in decision-making and when fully established only 
accept studies previously registered and reported on the portal. 
2. National Payers/HTA bodies 
Coverage/HTA Processes 
2.1 Encourage establishment of national processes for data collection, analysis, critical assessment and appraisal that enable collection of relevant 
and reliable RWD to inform access and reimbursement decisions and optimize use of highly innovative technologies to achieve the best outcomes 
for patients. 
2.2 Inform national stakeholders about RWE needs for HTA and engage in developments to enable secondary use of health and social care data in 
the national context. 
2.3 Seek to harmonize requests to Marketing Authorization Holders for additional RWD collection with other HTA bodies and the regulator. 
2.4 Engage with stakeholders to agree responsibility for the conduct and financing of RWD collection and analysis. 
2.5 Engage with patient organizations to ensure data is collected on those outcomes that matter most to patients. 
2.6 Build capacity in data analytics and critical assessment of RWE studies. 
Coverage/HTA Decisions for an Individual Technology 
2.7 Actively explore the opportunity to use RWD from other countries/across country (e.g. European registries), preferably in collaboration with other 
HTA bodies, in consultation with industry, taking account of national/context specific limitations of the data. 
2.8 Request RWE generation plans from companies, including protocols or plans for data collection and analysis of RWE studies related to HTA. 
2.9 During assessment, consider the feasibility of RWD collection, possibly combined with an outcomes-based managed entry agreement (nationally 
or in collaboration with other countries) to manage important uncertainties and enable reassessment. 
2.10 When an outcomes-based managed entry agreement is used, engage with patients and clinicians to plan for potential routine adoption or 







3.1 Promote use of parallel multi-HTA Scientific Advice/Early Dialogue processes including all relevant stakeholders at various points in the 
development of a highly innovative technology  
3.2 Develop, in co-creation with all stakeholders, guidance on generic RWE issues discussed in Scientific Advice/Early Dialogues for highly 
innovative technologies 
3.3 Continue to support methodological discussions with industry about non-randomized controlled trial (RCT) methodologies through methods 
qualification and multi-stakeholder scientific advice. 
3.4 Involve HTA bodies in initiatives related to improving the quality of RWD such as registry qualification, quality standards for big data/RWD etc. 
3.5 For highly innovative technologies with conditional Marketing Authorization (MA) or MA under exceptional circumstances, involve HTA bodies in 
discussions about requirements for post-marketing data collection. 
Pharmaceutical Industry 
4.1 Create a RWE generation plan early in development, which addresses essential data elements for HTA not covered in the clinical trial program 
and that might be studied in a real-world setting. 
4.2 Discuss the RWE generation plan at various stages throughout the technology life cycle including regulators, payers, HTA bodies, clinicians and 
patients whenever possible. 
4.3 Ensure the study (protocol) and statistical analysis plans for RWE studies that are answering major HTA questions are available to HTA bodies to 
provide transparency about the methods used to obtain and analyse data. 
4.4 Support the development of a public portal that provides details about the design and results of major RWE studies (ala RCT registries), 
particularly hypothesis evaluating treatment effect studies.  
4.5 Drive non-competitive, multi-company and multi-stakeholder collaborations about the development of robust RWE for diseases treated by highly 
innovative technologies. 
4.6 Enact recommendations from the ISPOR and RWE Transparency Partnership. 
4.7 Use reliable data collection methods for RWD, including ehealth and digital tools and develop best practices as digital approaches evolve. 
Registry-holders 
5.1 ERNs should continue to be developed and encouraged to engage with decision-makers to discuss registries and other sources of RWD.  
5.2 Collaborate with regulatory authorities, HTA bodies and industry at an early stage in the development of a highly innovative technology to identify 
if existing registries could be used to resolve uncertainties during the development phase or for post-launch data collection, or discuss potential for 
new registries.  
5.3 Review quality standards for registries issued by EMA and EUnetHTA and apply them. 
5.4 Collaborate on an ongoing basis with HTA bodies/regulatory authorities/manufacturers to determine if a standard set of data can be collected and 
shared to enable pooling with other data sources for analysis. 
5.5 Collaborate with European and national policy makers to develop governance structures that facilitate data quality and accessibility. 
5.6 Create incentives to build and maintain disease-based, rather than product-specific, registries. 
5.7 All Registries should follow the FAIR (Findable, Accessible, Interoperable, Re-usable) data principles and provide “privacy by design” – ensuring 
data protection through technology design. 






6.1 ERNs and other clinical networks should systematically collaborate with regulators and Payer/HTAs when establishing their registry or other form 
of RWD collection to ensure it is fit for all purposes including HTA. 
6.2 Enhance the H2020 EU Joint-Programme for rare diseases to include regulators and HTA bodies in order to better understand their needs. 
6.3 ERNs and other clinical networks should advise on the most suitable and efficient way for health systems to collect RWD.  
6.4 Encourage clinical communities to collect high quality health data (administrative, registry, audit etc) that is required for Payer/HTA decisions. 
6.5 Promote the use of data driven shared decision-making processes for optimization of treatment of the individual and care pathways. 
6.6 Understand the importance and relevance of the role of RWD in outcomes-based managed entry agreements in order to align on right usage and 
adherence to collect the data needed. 
Patient Groups 
7.1 Develop patient group expertise and capacity to be co-creators of RWE to ensure a holistic, patient-centred approach. 
7.2 Develop EU or international patient group collaborations to engage in RWD initiatives and ensure that outcomes that matter to patients are collected. 
7.3 Support the development of patient information and informed consent for RWE studies, clearly explaining study expectations (e.g. regularity of 
clinic visits and assessments) and treatment discontinuation rules.  
7.4 Disseminate clear unbiased, patient-relevant information about RWD and RWE to patient communities, including the value of secondary use of 
data 
7.5 Provide recommendations on novel and efficient collection methods for RWD (e.g. devices, wearables, mHealth).  
7.6 Help promote the scientific and policy value of data collection and provide access within strict governance frameworks ensuring appropriate 
confidentiality, e.g. via the #DataSavesLives initiative. 
7.7 Work with stakeholders to encourage alignment of views on identification, collection, analysis and evaluation of RWD for decision-making. 
RWD/analytics groups 
8.1 Engage with HTA bodies and other stakeholders in demonstration projects related to highly innovative technologies. 
8.2 Collaborate with industry and HTA bodies to generate RWE for outcomes-based Managed Entry Agreements (MEA). 
8.3 Contribute to research collaborations that lead to published guidance on the use of RWD for specific research questions relevant to HTA of highly 
innovative technologies  
8.4 Work with stakeholders to develop reporting standards, including full transparency, software audit trails and study pre-registration 
8.5 Collaborate with industry, regulators and HTA bodies to enhance the efficiency of preparation and submission of RWE that facilitates 
transparency, addresses proprietary data and privacy challenges and includes robust data governance. 
8.6 Work with stakeholders to develop criteria to evaluate RWD’s fitness for purpose, provenance, transparency and adherence to governance 
standards in order to inform the evaluation of RWE  
8.7 Publish analytical methods to generate reliable RWE for HTA. 
 
ERNs, European Reference Networks; FAIR, Findable Accessible Interoperable Re-usable; MA, Marketing Authorization; MEA, Managed Entry Agreement; 







In this initiative, case studies of recent Payer/HTA assessments about highly innovative 
technologies were considered against recent policy proposals relating to RWD. This showed 
a lack of clarity about the Payer/HTA questions that could be answered by RWD and how the 
quality of real-world evidence (RWE) could be assessed. All stakeholders worked together to 
create a vision whereby stakeholders agree what RWD can be collected for highly innovative 
technologies based on principles of collaboration and transparency. For each stakeholder 
group, recommended actions to support the generation, analysis and interpretation of RWD 
to inform decision-making were developed.   
 
At the outset of this work, the intention was to provide a one-page quick reference guide 
highlighting key actions that could be taken to develop RWE for highly innovative technologies. 
After the case studies, actions needed by HTA/Payers, regulatory bodies and industry were 
proposed. In this activity individuals identified that patient groups, registry holders and 
clinicians should also take responsibility for certain actions and so they were developed. In 
consultation, it became apparent that the stakeholder group of RWD/analytics organisations 
was missing. Actions were developed for this group based on the comments of the consultee 
and consulted upon with another analytics organisation and the Taskforce. Hence rather than 
a one-pager, a list of actions was created for each stakeholder group. This is important 
because central to the RWE4Decisions vision is that development of robust RWE is a shared 
responsibility. 
 
In Europe, collaboration across Members States is also essential, particular for very rare 
diseases, where study in one country will be insufficient.  
 
The EU’s new data strategy (10) promotes data-driven innovation to bring major benefits to 
citizens. Health is acknowledged as one of the sectors where Europe can benefit from the 
data revolution: improving the quality of healthcare, whilst decreasing costs, but this requires 
the right governance mechanisms to be put in place. To enable this, the European 
Commission (EC) will propose legislative or non-legislative measures for development of a 
European Health Data Space to promote health data exchange and support better diagnosis, 
care and outcomes for patients. It is an essential step for informed, evidence-based decisions 
to improve the accessibility, effectiveness and sustainability of the healthcare systems (11).  
  
In the EU, Public-Private partnerships, like the IMI Big Data for Better Outcomes projects 
provide important test beds for collation of data in a particular medical field and proof of 
concept for how data can be effectively shared to answer clinical questions. The GetReal 
Initiative has focused on methods development for RWD to inform both regulatory and HTA 
decision-making and is seeking a sustainable platform. 
 
RWE4Decisions has focussed on the EU given the imperative for cross border collaboration, 
but internationally other RWD initiatives are emerging that will be important to link with.  
 
The US FDA’s Sentinel program, involving over 100 million individuals, is a trusted source 
for pharmacovigilance. Building on that experience the FDA has created a RWE Program 
that will provide guidance on the relevance and reliability of RWD and the design and 
analysis of effectiveness studies to inform regulatory decisions. This will include 
demonstration projects and involve the FDA leadership to promote shared learnings and 
consistency of approaches across the Agency (7). 
 
The World Health Organization has stated that digital health initiatives need to be underpinned 
by a robust strategy that integrates financial, organizational, human and technological 
resources (8), recognizing legal constraints and national contexts.  Ideally, a legal framework, 




Europe via appropriate governance mechanisms for bona fide research and decision-making 
purposes, taking into consideration public concerns about commercialisation of patient and 
health system data. We are some distance away from that vision, but areas of progress are 
seen. The eHealth Digital Service Infrastructure enables sharing of prescription data and 
patient summaries between MS (11). Although only a small number of countries are currently 
involved, contribution and experience is building that will enhance future learning and 
collaboration. 
 
Essential to the RWE4Decision vision is that there is transparency in RWE generation. This 
is not simple given the need to maintain a competitive advantage that is obvious in any 
industry. However, the ISPOR RWE transparency taskforce is tackling this issue and will 
produce important findings agreed by all stakeholders in the future. 
 
In 2019, the HTAi Global Policy Forum noted that despite the promise of RWD, the HTA 
community is not yet fully equipped to address the challenges of using RWD (17).  They called 
for more clarity on methods, standards, streamlined collection of RWD, data sharing across 
jurisdictions, replication of RWD and expert analysis. It suggested that the HTA community 
should develop actions and guidance to develop and manage RWD/RWE to inform decision-
making. This paper seeks to respond to that by choosing a challenging area for Payers/HTA 
that could be informed by RWE and proposing actions for each stakeholder group.  But this is 
not enough. We need to embody continuous improvement cycles, reflecting on attempted 
actions, modifying them with experience. As a result, INAMI is undertaking meetings to provide 
informal advice on highly innovative technologies that are in development, taking account of 
the stakeholder actions, seeking to develop general learnings that can be shared. Other 
stakeholders are socializing RWE4Decisions in their networks and seeking link 
implementation with other initiatives such as #DataSavesLives. 
 
A Multi-Stakeholder EU Learning Network on RWE 
 
The Heads of Medicines Agency (HMA) and EMA have indicated that to develop use of Big 
Data in health, iterative approaches are needed with relevant stakeholders. This should 
support data standardization and improved data quality, promotion of data sharing and 
access, then robust data processing and analyses may be possible to produce RWE that 
has regulatory acceptability (22). To develop this work, they have issued ten 
recommendations that include delivery of a sustainable platform to access and analyse 
healthcare data from across the EU (DARWIN) (13). This is essential to enable cross border 
data sharing. An EU Big Data “stakeholder implementation forum” is also proposed to build a 
resource of key messages and communication materials on regulation and Big Data. The 
RWE4Decisions initiative is keen to see the development of this forum and following the 
multi-stakeholder work of INAMI over recent years, it is hoped that it will follow the ‘Bad 
Gastein’ principle in terms of breadth of participation to be collaborative “Learning Network”. 
This could use the EC’s Open Innovation 2.0 approach (23, 24), where all stakeholders work 
together to enable cross-fertilization of ideas to develop innovation far beyond the scope of 
what one organization or initiative can do alone. Järvensivu (25) provides guidance on 
learning, working and leading together in networks, which we have used to develop 
principles for a Learning Network as outlined in Box 1.   
 
The RWE4Decisions initiative can do its part in a multi-stakeholder EU Learning Network for 
RWE by continuing to bring together policy makers, payers, HTA bodies, regulatory bodies, 
clinicians, patient groups, industry and academic experts to share expertise as they try to 
implement these stakeholder actions. Keeping abreast of initiatives in other groups, piloting 
new processes with decision makers, discussing implementation challenges and reflecting 
on challenges and successes can all contribute to outputs and continuous learning to realise 




This is particularly important for areas where there is high unmet need and where EU cross 
border collaboration is most needed, in the area of rare diseases. 
 





















Highly innovative technologies make a good case study to consider how RWE can be 
developed through iterative multi-stakeholder dialogues to inform decisions by Payers/HTA 
bodies.  All stakeholders need to be involved, to agree what RWD is needed for what purpose, 
how it can be collected, when, by whom and how.  This includes considerations of cross-
border (cross-health system) HTA/regulatory collaboration to agree RWD requirements and 
the associated infrastructure, development of data analytics methods for HTA and 
transparency in RWE studies akin to that of RCTs. Demonstration projects on highly 
innovative technologies could realise some of the stakeholder actions presented in this paper, 
start to deliver some of the outputs and inform how new processes can be developed. This 
will provide substantial insights to a wider learning network that could develop systems to 
support a learning health system, optimization of health technology use and improvement in  










A Learning Network needs to: 
✓ be premised on open governance, reciprocity and legitimacy through 
comprehensive membership  
✓ enable knowledge sharing and dialogue, and operate on the basis of shared 
responsibilities and clear roles  
✓ be able to develop actions, to reach goals efficiently, and be able to question 
goals and practices to develop new learning methods  
✓ enable the attainment of common goals, develop network members’ own work, 
skill and capabilities 
 
 In order to deliver on the goals, the Learning Network must be:  
❑ Owned by a public institution 
❑ Enabling the multi-stakeholder interaction 
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